surpass cvot tirzepatide SURPASS-CVOT trial: was non-inferior to dulaglutide and superior to putative placebo for reducing the composite of CV death/HF events in patients with T2D and ASCVD. #AHA25 View the slides here: https://t.co/6VQpBHFP2I ACC 26: SURPASS-CVOT - Tirzepatide

Substance use disorder (especially alcoholism)

His innovative approach is tailored to replenish vital nutrients and support muscle repair following intense workouts or physical exertion

doi: 10.1136/bmjopen-2023-073971

Programs like Weight Watchers or medically supervised weight loss programs provide comprehensive support

Whats important to understand is this: The loss of lean mass seen in studies is not unique to tirzepatide Similar patterns occur with most forms of significant weight loss The ratio of fat loss to lean mass loss depends heavily on nutrition, exercise, and baseline health Clinical evidence suggests that when protein intake and resistance training are adequate, most of the weight lost on tirzepatide comes from fat rather than muscle